定坤丹联合炔诺酮治疗月经不调的临床研究

Clinical study on Dingkundan combined with norethisterone in treatment of menstrual disorders

目的探讨定坤丹联合炔诺酮治疗月经不调的临床疗效。方法选取2017年3月-2019年3月在开封市人民医院治疗的月经不调患者92例,根据用药的差别分为对照组(46例)和治疗组(46例)。对照组口服炔诺酮片,2.5mg/次,4次/d;治疗组在对照组基础上口服定坤丹,7 g/次,2次/d。两组患者均经过3个月经周期治疗。观察两组患者临床疗效,同时比较治疗前后两组患者临床症候积分、性激素水平、月经失血图(PBAC)、中华生存质量量表(Ch QOL)、高温相评分(HPS)、匹茨堡睡眠质量指数量表(PSQI)评分以及血清细胞因子水平。结果治疗后,对照组临床有效率为82.61%,显著低于治疗组的97.83%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者症候积分明显下降(P<0.05),且治疗组临床症候积分明显低于对照组(P<0.05)。治疗后,两组血清孕酮(P)、雌二醇(E2)水平显著升高(P<0.05),黄体生成激素(LH)、促卵泡成熟激素(FSH)水平显著下降(P<0.05),且治疗组E2、P、LH和FSH水平明显好于对照组(P<0.05)。治疗后,两组PBAC和PSQI评分显著下降(P<0.05),Ch QOL和HPS评分显著升高(P<0.05),且治疗组PBAC、PSQI、Ch QOL和HPS评分明显好于对照组(P<0.05)。治疗后,两组患者血清表皮生长因子(EGF)、血管内皮生长因子(VEGF)水平均明显升高(P<0.05),且治疗组EGF和VEGF水平明显高于对照组(P<0.05)。结论定坤丹联合炔诺酮片治疗月经不调可有效改善患者临床症状,改善机体性激素水平,提高患者睡眠和生活质量。

Objective To explore the clinical effect of Dingkundan combined with norethisterone in treatment of menstrual disorders.Methods Patients(92 cases) with menstrual disorders in Kaifeng People’s Hospital from March 2017 to March 2019 were divided into control(46 cases) and treatment(46 cases) groups based on different treatments. Patients in the control group were po administered with Norethisterone Tablets, 25 mg/time, four times daily. Patients in the treatment group were po administered with Dingkundan on the basis of the control group, 7 g/time, twice daily. Patients in two groups were treated for 3 menstrual cycles. After treatment, the clinical efficacy was evaluated, and the clinical symptom scores, sex hormone levels, PBAC, PSQI, ChQOL, and HPS scores, serum cytokine levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was82.61%, which was significantly lower than 97.83% in the treatment group, and there were differences between two groups(P <0.05). After treatment, the clinical symptom scores in two groups were significantly decreased(P < 0.05), and which in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the serum E2 and P levels in two groups were significantly increased(P < 0.05), but LH and FSH were significantly decreased(P < 0.05), and E2, P, LH, and FSH levels in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the PBAC and PSQI scores in two groups were significantly decreased(P < 0.05), but ChQOL and HPS scores were significantly increased(P < 0.05), and these scores in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the serum EGF and VEGF levels in two groups were significantly increased(P < 0.05), and EGF and VEGF levels in the treatment group were significantly higher than those in the control group(P < 0.05). Conclusion Dingkundan combined with norethisterone in treatment of menstrual disorders can effectively improve the clinical symptoms, the level of sex hormones, and improve the quality of sleep and life.